Publication

Abstract : Chronic systemic diseases are diseases which require long term drug therapy. Parenteral controlled drug delivery system is often used to treat these diseases. Vesicular bodies like liposome are commonly used as Parenteral controlled depot formulation. It possess disadvantage that they are rapidly removed from body by phagocytosis because they are considered as hapten. So formulating a slow release depot formulation is a challenge for pharmaceutical scientist.Erythrocytes as they are derived from human body, they serves as a potential carrier for loading drugs intended for chronic systemic diseases that require long term therapy. Erythrocytes unlike other carrier possess biocompatibility, biodegradability and have long circulation half-lives. They act as slow release depot formulation by following a zero order kinetic drug release profile and without being attack by the complement system, provided the method adopted for loading should not cause any structural deformity or disturbance in lipid packing. This review will give an insight to those researchers who wish to work with erythrocyte for using it as a slow release depot formulation.